| Literature DB >> 35074329 |
Xiang Zou1, Xi-Yu Tang1, Zhong-Yuan Qu2, Zhi-Wei Sun3, Chen-Feng Ji1, Yan-Jie Li4, Shou-Dong Guo5.
Abstract
Platelet-derived growth factors (PDGFs) and PDGF receptors (PDGFRs) are expressed in a variety of tumors. Activation of the PDGF/PDGFR signaling pathway is associated with cancer proliferation, metastasis, invasion, and angiogenesis through modulating multiple downstream pathways, including phosphatidylinositol 3 kinase/protein kinase B pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Therefore, targeting PDGF/PDGFR signaling pathway has been demonstrated to be an effective strategy for cancer therapy, and accordingly, some great progress has been made in this field in the past few decades. This review will focus on the PDGF isoforms and their binding with the related PDGFRs, the PDGF/PDGFR signaling and regulation, and especially present strategies and inhibitors developed for cancer therapy, and the related clinical benefits and side effects.Entities:
Keywords: Clinical trial; PDGF/PDGFR signaling; Platelet-derived growth factor; Small molecule inhibitor; Tumor therapy
Mesh:
Substances:
Year: 2022 PMID: 35074329 DOI: 10.1016/j.ijbiomac.2022.01.113
Source DB: PubMed Journal: Int J Biol Macromol ISSN: 0141-8130 Impact factor: 6.953